Back to homepage

Cardiology and cardiovascular disease

New and emerging lipid-modifying drugs to lower LDL cholesterol

Authors: Constantine E Kosmas, Dafni Pantou, Andreas Sourlas, Evangelia J Papakonstantinou, Rogers Echavarria Uceta, Eliscer Guzman

This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying low-density lipoprotein-cholesterol-lowering drugs.

More

Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm

Authors: Xavier Garcia-Moll, Vivencio Barrios, Josep Franch-Nadal

This article discusses how patients with diabetes should be treated
according to their CV risk considered as a continuum and not simply as falling within primary or secondary prevention.

More

Advances in safe insulin infusions

Authors: Fred Massoomi, Maureen Burger, Christine de Vries

This narrative review explores the expanding indications, risks and opportunities associated with insulin infusions and potential options for improved safety.

More

Ertugliflozin in the treatment of type 2 diabetes mellitus

Authors: Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

This narrative review aims to present and discuss the efficacy, safety, cardiovascular, and renal outcomes related to the use of ertugliflozin in Type 2 diabetes.

More

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease

Authors: Namrata Singhania MD, Saurabh Bansal MD, Shreya Mohandas, Divya P Nimmatoori MD, Abutaleb A Ejaz MD, Girish Singhania MD

This narrative review summarizes the role of renin–angiotensin–aldosterone system inhibitors in acute and chronic heart failure and chronic kidney disease.

More